Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 11/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12717410 | 0.91 | SCD (0.49) | SCDMAPTHSD17B3RAB9ALMNA | |
| SCHEMBL1576950 | 0.87 | SCD (0.61) | SCDRAB9ALMNATP53POLB | |
| SCHEMBL12717189 | 0.87 | HSD17B3 (0.48) | SCDMAPTHSD17B3RAB9A | |
| SCHEMBL1576789 | 0.85 | HSD17B3 (0.50) | SCDMAPTHSD17B3RAB9ALMNA | |
| SCHEMBL1576766 | 0.84 | HSD17B3 (0.51) | SCDHSD17B3RAB9ALMNA | |
| SCHEMBL12717837 | 0.77 | SCD (0.46) | SCD | |
| SCHEMBL27862618 | 0.77 | HSD17B3 (0.47) | SCDHSD17B3RAB9A | |
| SCHEMBL27878887 | 0.72 | SCD (0.52) | SCDMAPT | |
| SCHEMBL27878888 | 0.71 | SCD (0.51) | SCDMAPT | |
| SCHEMBL1577114 | 0.67 | HDAC1 (0.49) | SCDMAPTRAB9ALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2013-01-10 | — | — | US | disclosed |
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2013-01-10 | — | — | US | disclosed |
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2013-01-10 | — | — | US | disclosed |
| EP-2483264-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | Novartis AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039358-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130011361-A1 | PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | SCD 1/4885MAPT 4129/4885HSD17B3 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.